610 related articles for article (PubMed ID: 29403271)
1. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.
Tashkin DP; Wechsler ME
Int J Chron Obstruct Pulmon Dis; 2018; 13():335-349. PubMed ID: 29403271
[TBL] [Abstract][Full Text] [Related]
2. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease.
Zanini A; Cherubino F; Zampogna E; Croce S; Pignatti P; Spanevello A
Int J Chron Obstruct Pulmon Dis; 2015; 10():1155-61. PubMed ID: 26124655
[TBL] [Abstract][Full Text] [Related]
3. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD.
Gao J; Zhang M; Zhou L; Yang X; Wu H; Zhang J; Wu F
Int J Chron Obstruct Pulmon Dis; 2017; 12():1287-1293. PubMed ID: 28490872
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
Pavord ID; Lettis S; Anzueto A; Barnes N
Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilic COPD - a distinct phenotype of the disease.
Tworek D; Antczak A
Adv Respir Med; 2017; 85(5):271-276. PubMed ID: 29083023
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
7. Airway inflammation and mannitol challenge test in COPD.
de Nijs SB; Fens N; Lutter R; Dijkers E; Krouwels FH; Smids-Dierdorp BS; van Steenwijk RP; Sterk PJ
Respir Res; 2011 Jan; 12(1):11. PubMed ID: 21241520
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic airway inflammation in COPD.
Saha S; Brightling CE
Int J Chron Obstruct Pulmon Dis; 2006; 1(1):39-47. PubMed ID: 18046901
[TBL] [Abstract][Full Text] [Related]
9. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
10. Targeting IL-5 in COPD.
Narendra DK; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2019; 14():1045-1051. PubMed ID: 31190789
[TBL] [Abstract][Full Text] [Related]
11. The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD.
Tworek D; Majewski S; Szewczyk K; Kiszałkiewicz J; Kurmanowska Z; Górski P; Brzeziańska-Lasota E; Kuna P; Antczak A
Respir Res; 2018 Jun; 19(1):108. PubMed ID: 29859068
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease.
Sohal SS; Ward C; Danial W; Wood-Baker R; Walters EH
Expert Rev Respir Med; 2013 Jun; 7(3):275-88. PubMed ID: 23734649
[TBL] [Abstract][Full Text] [Related]
13. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.
Greulich T; Hohlfeld JM; Neuser P; Lueer K; Klemmer A; Schade-Brittinger C; Harnisch S; Garn H; Renz H; Homburg U; Renz J; Kirsten A; Pedersen F; Müller M; Vogelmeier CF; Watz H
Respir Res; 2018 Apr; 19(1):55. PubMed ID: 29615049
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.
Vestbo J; Vogelmeier CF; Small M; Siddall J; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2019; 14():853-861. PubMed ID: 31114183
[No Abstract] [Full Text] [Related]
15. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD.
Kang HS; Rhee CK; Kim SK; Kim JW; Lee SH; Yoon HK; Ahn JH; Kim YH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2467-2473. PubMed ID: 27757029
[TBL] [Abstract][Full Text] [Related]
16. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation.
Bathoorn E; Liesker JJ; Postma DS; Koëter GH; van der Toorn M; van der Heide S; Ross HA; van Oosterhout AJ; Kerstjens HA
Int J Chron Obstruct Pulmon Dis; 2009; 4():101-9. PubMed ID: 19436694
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
18. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.
Liesker JJ; Bathoorn E; Postma DS; Vonk JM; Timens W; Kerstjens HA
Respir Med; 2011 Dec; 105(12):1853-60. PubMed ID: 21802933
[TBL] [Abstract][Full Text] [Related]
19. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma.
Jeffery P
Expert Opin Investig Drugs; 2005 May; 14(5):619-32. PubMed ID: 15926868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
